Sciele Pharma, Inc., a U.S.-based group of Shionogi & Co., Ltd., has entered an agreement to acquire and Addrenex Pharmaceuticals, a private, specialty pharmaceutical company, for approximately $29 million in cash. Addrenex specializes in developing drugs that regulate the adrenergic system. Sciele previously licensed three products from Addrenex: Clonicel for attention deficit hyperactivity disorder (ADHD), Jenloga XR for hypertension, and ADX-415 for the treatment of vasomotor systems a...